CYP2D6 genotypes in association with steady state plasma concentrations of active metabolites of tamoxifen in patients with breast cancer.

被引：0
|
作者：
Lim, H.
Lee, H.
Lee, K.
Lee, E.
Jang, I.
Ro, J.
机构：
[1] Natl Canc Ctr, Res Inst & Hosp, Gyeonggi, South Korea
[2] Natl Canc Ctr, Gyeonggi, South Korea
[3] Seoul Natl Univ, Coll Med, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：36S / 36S
页数：1
相关论文
共 50 条
  • [41] Tamoxifen Use in Postmenopausal Breast Cancer: CYP2D6 Matters
    Brauch, Hiltrud
    Schroth, Werner
    Goetz, Matthew P.
    Muerdter, Thomas E.
    Winter, Stefan
    Ingle, James N.
    Schwab, Matthias
    Eichelbaum, Michel
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (02) : 176 - 180
  • [42] CYP2D6 GENOTYPING TO GUIDE USE OF TAMOXIFEN IN BREAST CANCER
    Irvin, William J., Jr.
    Weck, Karen E.
    Walko, Christine M.
    Ibrahim, Joseph G.
    Chiu, Wing. K.
    Dees, E. Claire
    Ogburn, Evan T.
    Desta, Zeruesenay
    Flockhart, David A.
    McLeod, Howard L.
    Evans, James P.
    Carey, Lisa A.
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2011, 49 : S88 - S88
  • [43] Optimized CYP2D6 phenotype assignment for plasma endoxifen prediction in breast cancer patients treated with tamoxifen
    Schroth, Werner
    Winter, Stefan
    Eichelbaum, Michel
    Muerdter, Thomas
    Schwab, Matthias
    Brauch, Hiltrud
    CANCER RESEARCH, 2017, 77
  • [44] Influence of CYP2D6 Polymorphisms on Serum Levels of Tamoxifen Metabolites in Spanish Women with Breast Cancer
    Zafra-Ceres, Mercedes
    de Haro, Tomas
    Farez-Vidal, Esther
    Blancas, Isabel
    Bandres, Fernando
    de Duenas, Eduardo Martinez
    Ochoa-Aranda, Enrique
    Gomez-Capilla, Jose A.
    Gomez-Llorente, Carolina
    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2013, 10 (07): : 932 - 937
  • [45] Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment
    Charoenchokthavee, Wanaporn
    Panomvana, Duangchit
    Sriuranpong, Virote
    Areepium, Nutthada
    BREAST CANCER-TARGETS AND THERAPY, 2016, 8 : 149 - 155
  • [46] CONCOMITANT CYP2D6 INHIBITOR USE AND PLASMA METABOLITE LEVELS IN BREAST CANCER PATIENTS TREATED WITH TAMOXIFEN
    Fox, P.
    Balakrishnar, B.
    Menzies, A.
    Liddle, C.
    Coulter, S.
    Provan, P.
    Gebski, V.
    Hui, R.
    Kefford, R.
    Wilcken, N.
    Balleine, R.
    Gurney, H.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2012, 8 : 52 - 52
  • [47] Association Between CYP2D6 Genotypes and Serum Concentrations of Mirtazapine and Mianserin
    Hole, Kristine
    Molden, Espen
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2025, 136 (04)
  • [48] Estimation of tamoxifen metabolite concentrations in the blood of breast cancer patients through CYP2D6 genotype activity score
    Alan H. B. Wu
    Wendy Lorizio
    Simone Tchu
    Kara Lynch
    Roy Gerona
    Wuyang Ji
    Weiming Ruan
    Kathryn J. Ruddy
    Stephen D. Desantis
    Harold J. Burstein
    Elad Ziv
    Breast Cancer Research and Treatment, 2012, 133 : 677 - 683
  • [49] Estimation of tamoxifen metabolite concentrations in the blood of breast cancer patients through CYP2D6 genotype activity score
    Wu, Alan H. B.
    Lorizio, Wendy
    Tchu, Simone
    Lynch, Kara
    Gerona, Roy
    Ji, Wuyang
    Ruan, Weiming
    Ruddy, Kathryn J.
    Desantis, Stephen D.
    Burstein, Harold J.
    Ziv, Elad
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 133 (02) : 677 - 683
  • [50] Predicting steady-state endoxifen plasma concentrations in breast cancer patients by CYP2D6 genotyping or phenotyping. Which approach is more reliable?
    Gusella, Milena
    Pasini, Felice
    Corso, Barbara
    Bertolaso, Laura
    De Rosa, Giovanni
    Falci, Cristina
    Modena, Yasmina
    Barile, Carmen
    Da Corte, Donatella Z.
    Fraccon, AnnaPaola
    Toso, Silvia
    Cretella, Elisabetta
    Brunello, Antonella
    Modonesi, Caterina
    Segati, Romana
    Oliani, Cristina
    Minicuci, Nadia
    Padrini, Roberto
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2020, 8 (05):
12345